| Lillehei, Kevin O |
SONOBIRD, NCT05902169: Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM |
|
|
| Recruiting | 3 | 560 | Europe, US | SonoCloud-9 (SC9), Carboplatin, CycloButane DiCarboxylic Acid (CBDCA), Lomustine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), Temozolomide, Temodal | CarThera | Glioblastoma, Recurrent Glioblastoma, GBM | 01/28 | 06/28 | | |
DCVax-L EAP, NCT02146066: Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 |
|
|
| Available | N/A | | US | DCVax-L | Northwest Biotherapeutics | GBM, Glioblastoma Multiforme | | | | |
| Messersmith, Wells |
AGICC, NCT02723331: Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates |
|
|
| Active, not recruiting | 2 | 48 | US | Nab paclitaxel, Abraxane, Gemcitabine, Gemzar | Academic Thoracic Oncology Medical Investigators Consortium, Celgene Corporation, Criterium, Inc., University of Colorado, Denver | Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma | 12/22 | 05/25 | | |
| Active, not recruiting | 2 | 234 | Europe, US, RoW | Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care | Agenus Inc. | Metastatic Colorectal Cancer | 02/25 | 07/25 | | |
NCT05167409: A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 48 | US | Evorpacept (ALX148), evorpacept, Cetuximab, Erbitux, Pembrolizumab, Keytruda | University of Colorado, Denver, ALX Oncology Inc., Merck Sharp & Dohme LLC, Eli Lilly and Company, Criterium, Inc., Academic GI Cancer Consortium (AGICC) | Microsatellite Stable Metastatic Colorectal Cancer | 12/25 | 03/26 | | |
| Recruiting | 1 | 345 | Europe, US | NX-1607, Cbl-b Inhibitor, Paclitaxel | Nurix Therapeutics, Inc. | Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma | 08/26 | 02/28 | | |
| Berman, Brian |
NCT06771323: Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia |
|
|
| Not yet recruiting | 2 | 20 | US | Valbenazine, Placebo | Virginia Commonwealth University, Neurocrine Biosciences | Cervical Dystonia | 01/26 | 01/26 | | |
NCT05157763: A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma |
|
|
| Recruiting | 1/2 | 32 | US | EscharEx 5% (EX-02 formulation), EX-02 5% | MediWound Ltd | Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma | 05/22 | 06/22 | | |
CNXR-001D, NCT05279495: Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers |
|
|
| Completed | N/A | 20 | US | In a double-blinded fashion, 250 mg CANNAXR cream, TOPICAL CBD CANNAXR Cream, Topical VEHICLE cream | MINO Labs, LLC | Photoaging | 04/23 | 05/23 | | |
| Wang, Michael |
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD) |
|
|
| Active, not recruiting | 3 | 38 | Europe, US, RoW | rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Von Willebrand Disease (VWD) | 03/25 | 03/25 | | |
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) |
|
|
| Recruiting | 3 | 34 | Europe, US, RoW | von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Von Willebrand Disease | 01/25 | 01/25 | | |
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial |
|
|
| Recruiting | 3 | 150 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor | 11/28 | 11/28 | | |
| Active, not recruiting | 2 | 3 | Europe, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia B with Inhibitor, Hemophilia B | 11/24 | 02/25 | | |
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B |
|
|
| Active, not recruiting | 2 | 60 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B | 11/24 | 02/25 | | |
NCT04014205: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies |
|
|
| Active, not recruiting | 1/2 | 81 | Europe, US, RoW | Orelabrutinib (ICP-022) | Beijing InnoCare Pharma Tech Co., Ltd. | Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies | 12/23 | 01/25 | | |
| Terminated | 1/2 | 9 | US | ONCT-808, Bridging Therapy | Oncternal Therapeutics, Inc | Relapsed/Refractory Aggressive B-Cell Malignancies | 09/24 | 09/24 | | |
| Completed | N/A | 65 | US | VIO Imaging | Enspectra Health, National Cancer Institute (NCI), National Institutes of Health (NIH) | Skin Condition, Skin Diseases, Skin Lesion, Skin Abnormalities, Skin Cancer | 08/23 | 08/23 | | |
| Active, not recruiting | N/A | 108 | US | | American Thrombosis and Hemostasis Network, Takeda | Von Willebrand Diseases | 12/24 | 01/25 | | |
NCT05568459: A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy |
|
|
| Recruiting | N/A | 120 | Europe, Canada, US | Non-Interventional | Regeneron Pharmaceuticals | Hemophilia B | 04/26 | 04/26 | | |
| Ginde, Adit A |
| Completed | N/A | 815 | Europe, US, RoW | | BioMérieux, Vanderbilt University Medical Center, Centre d'Investigation Clinique - Limoges | Infection, Sepsis | 05/22 | 05/22 | | |
| Wicklund, Matthew |
Fortify, NCT05775848: Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) |
|
|
| Active, not recruiting | 3 | 81 | Europe, US, RoW | BBP-418 (ribitol), Placebo | ML Bio Solutions, Inc. | Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) | 07/27 | 07/27 | | |
NCT04886518: Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 |
|
|
| Active, not recruiting | 2 | 30 | Canada, US | Pitolisant Oral Tablet, Placebo oral tablet | Harmony Biosciences, LLC | Myotonic Dystrophy 1, Excessive Daytime Sleepiness | 10/23 | 10/24 | | |
|
| Recruiting | N/A | 450 | Europe, Canada, US | | University of Kansas Medical Center, FSHD Society, Inc., Friends Research Institute, Inc., University of Rochester, University of Nevada, Reno, FSHD Canada, Avidity Biosciences, Inc., AMRA Medical, Seattle Children's Hospital, Dyne Therapeutics, Hoffmann-La Roche | FSHD | 12/26 | 01/27 | | |
| Recruiting | N/A | 80 | Europe, US, RoW | | Virginia Commonwealth University, Edgewise Therapeutics, Inc. | Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker | 05/25 | 05/26 | | |
| Castorino, Kristin |
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
|
|
| Completed | 4 | 141 | US | Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1 | 03/24 | 06/24 | | |
TRZ, NCT06009653: Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity |
|
|
| Terminated | 4 | 32 | US | Standard Care, Culturally-tailored dietary and behavioral intensive lifestyle intervention, Placebo, Tirzepatide | Washington University School of Medicine, Eli Lilly and Company, National Institute on Minority Health and Health Disparities (NIMHD) | Obesity, Metabolic Disease | 05/24 | 05/24 | | |
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy |
|
|
| Completed | 3 | 692 | Europe, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Type 1 Diabetes, Diabetes | 05/24 | 05/24 | | |
INHALE-GDM, NCT06535789: Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes |
|
|
| Not yet recruiting | 2/3 | 30 | US | Inhaled Technosphere Insulin | Jaeb Center for Health Research, Mannkind Corporation | Diabetes, Gestational, Pregnancy Complications, Glucose Metabolism Disorders, Glucose Intolerance During Pregnancy | 12/24 | 12/24 | | |
NCT04905628: Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus |
|
|
| Recruiting | N/A | 100 | US | Dexcom CGM System | DexCom, Inc. | Diabetes Mellitus | 03/22 | 04/22 | | |
| Active, not recruiting | N/A | 200 | Europe, US | Omnipod 5 System | Insulet Corporation | Type 1 Diabetes | 09/23 | 01/25 | | |
| Completed | N/A | 343 | US | Omnipod 5 Automated Glucose Control System | Insulet Corporation, Jaeb Center for Health Research | Type2 Diabetes | 03/24 | 03/24 | | |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Bennett, Jeffrey |
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes |
|
|
| Terminated | N/A | 138 | US | | LivaNova | Treatment Resistant Depression | 09/24 | 09/24 | | |
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression |
|
|
| Recruiting | N/A | 6800 | US | Vagus Nerve Stimulation (VNS), VNS | LivaNova | Treatment Resistant Depression | 02/28 | 12/30 | | |
| Lee, Joyce |
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 2/3 | 300 | Europe, Japan, US, RoW | Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | 07/27 | 07/27 | | |
|
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
| Monte, Andrew |
NCT06017622: Observational Study of THC Concentrations in Acute Cannabinoid Intoxication |
|
|
| Recruiting | N/A | 120 | US | | Anebulo Pharmaceuticals | Acute Cannabinoid Intoxication | 06/25 | 06/25 | | |
| Forman, Lisa |
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy |
|
|
| Terminated | 4 | 6 | US | Placebo, Rifaximin, XIFAXAN® Tablets | Bausch Health Americas, Inc. | Hepatic Encephalopathy | 02/16 | 02/16 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
NCT05569759: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) |
|
|
| Active, not recruiting | 2 | 24 | US | zetomipzomib, KZR-616, placebo, sterile water for injection, zetomipzomib in open-label extension | Kezar Life Sciences, Inc. | Autoimmune Hepatitis | 02/25 | 08/25 | | |
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC |
|
|
| Not yet recruiting | 2 | 87 | US | LB-P8 low-dose, LB-P8 high-dose, Placebo | LISCure Biosciences | Primary Sclerosing Cholangitis (PSC) | 03/28 | 02/29 | | |
| Genuario, James |
| Terminated | N/A | 12500 | Europe, Canada, US, RoW | | Arthrex, Inc. | Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip | 07/23 | 07/23 | | |
NCT06320925: SportsPro: Post-Market Clinical Follow Up Study |
|
|
| Recruiting | N/A | 1500 | US | Standard of Care Treatment | Stryker Endoscopy | Shoulder Injuries, Knee Injuries, Hip Injuries | 06/24 | 12/24 | | |
| Recruiting | N/A | 160 | US | InSpace Subacromial Tissue Spacer | Stryker Endoscopy | Rotator Cuff Tears | 04/25 | 04/26 | | |
| Kleck, Christopher |
| Recruiting | N/A | 1017 | US, RoW | Infuse™ Bone Graft (Infuse™), Intervertebral body fusion device and Medtronic posterior Fixation Systems | Medtronic Spinal and Biologics | Degenerative Disease of the Lumbosacral Spine | 04/26 | 04/28 | | |
| Recruiting | N/A | 200 | US | iFuse Bedrock Granite Implant System, GRANITE, Bedrock Granite | SI-BONE, Inc. | Spinal Fusion, Deformity of Spine | 11/26 | 12/26 | | |
| Kabos, Peter |
DARE, NCT04567420: DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 70 | US | Palbociclib, IBRANCE, Fulvestrant, Faslodex, Adjuvant Therapy, Standard of Care | Criterium, Inc. | Breast Cancer | 12/27 | 12/27 | | |
| Recruiting | 1/2 | 44 | US | Abemaciclib, Verzenio, Elacestrant | Criterium, Inc. | Breast Cancer | 12/24 | 01/25 | | |
| Recruiting | N/A | 422 | US | | Personalis Inc. | TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease | 08/25 | 12/25 | | |
| Striebich, Christopher |
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate |
|
|
| Completed | 4 | 191 | US | Pegloticase with MTX, Methotrexate | Amgen | Chronic Uncontrolled Gout, Gout, Uncontrolled Gout | 01/24 | 03/24 | | |
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 540 | Europe, US, RoW | Litifilimab, BIIB059, Placebo | Biogen | Lupus Erythematosus, Systemic | 09/26 | 03/27 | | |
|
| Recruiting | 3 | 406 | Europe, Canada, Japan, US, RoW | Ianalumab, VAY736, Placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Systemic Lupus Erythematosus | 01/27 | 04/29 | | |
| Corr, Bradley R |
| Recruiting | 3 | 220 | Europe, Canada, US, RoW | Selinexor, KPT-330, Matching Placebo for selinexor | Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group | Endometrial Cancer | 01/25 | 01/28 | | |
|
NCT03617679: Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer |
|
|
| Active, not recruiting | 2 | 79 | US | Rucaparib, Placebo Oral Tablet | University of Colorado, Denver, Clovis Oncology, Inc., National Cancer Institute (NCI) | Metastatic Endometrial Cancer | 10/23 | 12/24 | | |
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers |
|
|
| Completed | 2 | 79 | Europe, Canada, US, RoW | Mirvetuximab soravtansine, MIRV, IMGN853 | AbbVie | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 01/24 | 12/24 | | |
|
|
|
|
NCT05887609: An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib |
|
|
| Recruiting | 2 | 53 | US | Mirvetuximab Soravtansine, IMGN853, MIRV, Olaparib | University of Colorado, Denver, ImmunoGen, Inc. | Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 04/26 | 12/27 | | |
| Recruiting | 1 | 423 | US | IMGN151 | AbbVie | Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer | 02/27 | 02/27 | | |
| Maitlen, Jennifer |
NCT05113381: The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of IVH |
|
|
| Recruiting | N/A | 109 | US | CerebroFlo™ EVD Catheter | Integra LifeSciences Corporation | Intraventricular Hemorrhage, Subarachnoid Hemorrhage | 10/24 | 12/24 | | |
| Haakonsen, Nicola |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
| Recruiting | N/A | 26 | US | Vertebral Body Augmentation, Manual Surgical Instruments | Lenoss Medical, MCRA, LLC | Vertebral Body Compression Fracture(s) | 08/22 | 12/22 | | |
| Averill, Francis |
NCT05156047: A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia |
|
|
| Completed | 3 | 214 | US | Open-label pitolisant, Double-blind placebo, Double-blind pitolisant | Harmony Biosciences, LLC | Idiopathic Hypersomnia | 09/23 | 09/23 | | |
| Completed | 3 | 806 | Europe, Canada, US, RoW | Placebo, Mepolizumab | GlaxoSmithKline, PPD DEVELOPMENT, LP | Pulmonary Disease, Chronic Obstructive | 08/24 | 08/24 | | |
|
|
|
|
|
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension |
|
|
| Recruiting | 3 | 234 | US | Clofazimine Inhalation Suspension, MNKD-101, Placebo | Mannkind Corporation | MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous | 08/26 | 12/28 | | |
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 576 | Canada, US | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 06/25 | 06/25 | | |
|
|
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy |
|
|
| Completed | 2 | 190 | Canada, US | SUVN-G3031, Samelisant, Placebo | Suven Life Sciences Limited | Narcolepsy | 06/23 | 06/23 | | |
NCT05668754: Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH |
|
|
| Completed | 2 | 50 | US | Serdexmethylphenidate, SDX, Placebo | Zevra Therapeutics, Rho, Inc. | Idiopathic Hypersomnia | 02/24 | 03/24 | | |
| Completed | 2 | 66 | US | Omadacycline Oral Tablet, Nuzyra, Placebo, placebo tablets | Paratek Pharmaceuticals Inc | Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection | 06/24 | 07/24 | | |
| Active, not recruiting | 2 | 129 | Europe, US, RoW | BBT-877, Placebo | Bridge Biotherapeutics, Inc. | Idiopathic Pulmonary Fibrosis | 01/25 | 09/25 | | |
|
|
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
| Holden, Samantha |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies |
|
|
| Completed | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia with Lewy Bodies | 11/24 | 11/24 | | |
| Active, not recruiting | 2 | 160 | Europe, US | Neflamapimod, VX-745, Placebo | EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc | Dementia With Lewy Bodies | 08/24 | 03/25 | | |
| Chambers, Carrie |
| Active, not recruiting | 3 | 719 | Japan, US, RoW | Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label) | National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies | MPOX | 10/24 | 09/25 | | |
| Ahmed, Waseem |
NCT05666960: R-3750 in Patients With Mild to Moderate Ulcerative Colitis |
|
|
| Recruiting | 1 | 36 | US | R-3750 | Rise Therapeutics LLC, Mayo Clinic, University of Colorado, Denver | Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic, Ulcerative Colitis | 09/25 | 10/25 | | |
| Active, not recruiting | N/A | 40 | US | Neuromodulation | Boomerang Medical | IBD | 12/24 | 12/24 | | |
| Subramanian, Prem |
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study |
|
|
| Active, not recruiting | 4 | 313 | Europe, US | Teprotumumab, TEPEZZA, Placebo, Saline Solution | Amgen | Thyroid Eye Disease | 04/26 | 04/26 | | |
| Active, not recruiting | 3 | 154 | Europe, Canada, US, RoW | Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo | Viridian Therapeutics, Inc., Viridian Therapeutics, Inc. | Thyroid Eye Disease | 07/24 | 03/25 | | |
| Foster, Laura |
| Active, not recruiting | 2 | 40 | US, RoW | Fasudil (WP-0512) | Woolsey Pharmaceuticals | Amyotrophic Lateral Sclerosis | 07/26 | 01/28 | | |
ALSpire, NCT04494256 / 2020-000207-36: A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation |
|
|
| Terminated | 1/2 | 99 | Europe, Canada, US | BIIB105, Placebo | Biogen, Biogen Idec Research Limited | Amyotrophic Lateral Sclerosis | 08/24 | 08/24 | | |
| No Longer Available | N/A | | US | Trehalose, SLS-005 Intravenous Trehalose Injection 90.5 mg/mL | Seelos Therapeutics, Inc., Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) | Amyotrophic Lateral Sclerosis | | | | |
| Capobianco, Robyn |
NCT05870488: iFuse TORQ for the Treatment of Sacroiliac Joint Dysfunction |
|
|
| Active, not recruiting | 4 | 110 | US | Use of iFuse TORQ | SI-BONE, Inc. | Sacroiliac Joint Dysfunction, Sacroiliac; Fusion, Sacroiliac Disorder, Sacroiliac Joint Pain | 05/25 | 11/27 | | |
| Terminated | N/A | 28 | US | Surgical Intervention, Non-Surgical Management | SI-BONE, Inc. | Fracture;Pelvis, Sacral Fracture, Sacroiliac; Fusion, Fragility Fracture, Insufficiency Fractures, Osteoporosis | 06/24 | 06/24 | | |
| Enrolling by invitation | N/A | 1000 | US | Health questionnaires | SI-BONE, Inc. | Sacroiliac Joint Dysfunction, Sacroiliac Joint Pain | 12/34 | 12/34 | | |
| Recruiting | N/A | 200 | US | iFuse Bedrock Granite Implant System, GRANITE, Bedrock Granite | SI-BONE, Inc. | Spinal Fusion, Deformity of Spine | 11/26 | 12/26 | | |
| Dylla, Layne |
NCT06017622: Observational Study of THC Concentrations in Acute Cannabinoid Intoxication |
|
|
| Recruiting | N/A | 120 | US | | Anebulo Pharmaceuticals | Acute Cannabinoid Intoxication | 06/25 | 06/25 | | |
| Hamed, Amen |
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension |
|
|
| Recruiting | 3 | 234 | US | Clofazimine Inhalation Suspension, MNKD-101, Placebo | Mannkind Corporation | MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous | 08/26 | 12/28 | | |
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 576 | Canada, US | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 06/25 | 06/25 | | |
|
|
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 698 | Canada, US, RoW | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Progressive Pulmonary Fibrosis, Interstitial Lung Disease | 11/27 | 11/27 | | |
NCT05495243: Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough |
|
|
| Completed | 2 | 40 | US | ARINA-1, Placebo | Renovion, Inc. | Non-cystic Fibrosis Bronchiectasis | 02/24 | 02/24 | | |
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection |
|
|
| Completed | 2 | 48 | US | AP-PA02, Placebo | Armata Pharmaceuticals, Inc. | Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection | 07/24 | 08/24 | | |
| Completed | 2 | 66 | US | Omadacycline Oral Tablet, Nuzyra, Placebo, placebo tablets | Paratek Pharmaceuticals Inc | Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection | 06/24 | 07/24 | | |
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
| Morales, Gianna |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
| Active, not recruiting | 2 | 60 | US | Seton Placement, AVB-114 | Avobis Bio, LLC, Alimentiv Inc. | Perianal Fistula, Crohn's Disease | 05/25 | 08/26 | | |
| Baines, Brenna |
NCT04886518: Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 |
|
|
| Active, not recruiting | 2 | 30 | Canada, US | Pitolisant Oral Tablet, Placebo oral tablet | Harmony Biosciences, LLC | Myotonic Dystrophy 1, Excessive Daytime Sleepiness | 10/23 | 10/24 | | |
|
| Simpson, Haley |
BEAT-MS, NCT04047628: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis |
|
|
| Recruiting | 3 | 156 | US | Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Best Available Therapy (BAT), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), rituximab (Rituxan®), cladribine (Mavenclad®), ofatumumab (Kesimpta®), ublituximab (BRIUMVI™) | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Blood and Marrow Transplant Clinical Trials Network, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc. | Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | 10/26 | 10/29 | | |
| Hao, Jiandong |
| Recruiting | N/A | 200 | US | Lumbar Interbody Fusion | 3Spine, MCRA | Lumbar Spine Degeneration | 05/24 | 08/26 | | |
NCT04982835: M6®-C Artificial Cervical Disc Two-Level IDE Pivotal Study |
|
|
| Recruiting | N/A | 263 | US | M6-C Artificial Cervical Disc, ACDF | Spinal Kinetics | Cervical Disc Degenerative Disorder | 12/24 | 12/25 | | |
